Navigation Links
Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
Date:9/12/2007

Tallahassee Dermatologist Encourages Regular Skin Examinations

TALLAHASSEE, Fla., Sept. 12 /PRNewswire/ -- Once every two hours a Florida resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease this alarming statistic, and increase the likelihood that local residents diagnosed with this deadliest type of skin cancer will survive.

"Staying out of the sun or protecting your skin from harmful ultraviolet rays is the best defense against skin cancer, but it's equally important to have your skin examined at least once a year by a board-certified dermatologist, especially if you have any moles that are irregular in shape or have recently appeared or changed in size, shape or color," said Dr. Armand Cognetta, medical co-director of the nationwide trial of Dermatology Associates of Tallahassee. "Early detection of suspicious moles is the key to preventing melanoma."

When melanoma is caught in its early stages, it's almost always curable.

Risk factors for melanoma include:

* Sunlight, or too much exposure to ultraviolet radiation

* Presence of many moles and/or large moles (>6mm)

* Fair skin, freckling, light eyes, or natural red or blond hair

* Family history of melanoma

* Past personal history of melanoma

Traditionally, dermatologists have relied on their own eyes and judgment in deciding whether to remove a suspicious mole.

Dermatology Associates of Tallahassee is participating in a nationwide patient trial to test an investigational medical technology called MelaFind(R), designed to assist physicians in the early diagnosis of melanoma.

MelaFind is a non-invasive hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions (moles). MelaFind then analyzes the images in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

"We encourage patients to come in for skin exams in general, especially during the summer months when people tend to spend a lot of time outdoors in the sun," said Dr. Cognetta.

If you think you have a mole that may be cancerous, and would like to have it examined, please contact Dermatology Associates of Tallahassee at 850-877-4134. You may also be eligible to participate in the MelaFind trial.

About Dermatology Associates of Tallahassee

Dermatology Associates of Tallahassee is proud to have served the community for over 20 years. We are your skin cancer management professionals providing examination and treatment of skin lesions and disease. We have seven dermatologists on staff, and pride our self in offering complete skin care management, Mohs micrographic surgery, Puva light therapy, and radiation treatment. Dr. Cognetta is the medical co-director of the MelaFind trial and is only one of forty directors of the American College of Mohs Micrographic Surgery fellowship. Dr. Cognetta has devoted and built his practice in skin cancer detection and treatment over the last seventeen years.

Media Contact:

Erich Sandoval, Lazar Partners

Tel: (212) 867-1762

esandoval@lazarpartners.com


'/>"/>
SOURCE Dermatology Associates of Tallahassee
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017   Dynatronics Corporation (NASDAQ: ... of Cynthia L. McHenry (Cyndi) as ... for leading Dynatronics manufacturing, distribution, and purchasing operations ... Dynatronics, CEO Kelvyn H. Cullimore, Jr. ... search process conducted by the company as it ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research report ... will reach a value of USD 55.8 billion by 2025. The projection ... United States and a more open approach towards cannabis products ... Florida , North Dakota , ...
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 ... ... Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American ... The organization, which plans to publish the first ANSI-approved GMP standard for ...
(Date:3/29/2017)... , ... March 29, 2017 , ... HealthCareMandA.com will host ... April 20, 2017, at 1:00 PM ET. A recording of the webinar will also ... Webinar Series. , Home health and hospice companies are still popular targets for healthcare ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education ... specialized continuing medical education conference for clinicians who manage some of the most ... York. , The program will be led by co- chairs Dr. John ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the ... take the Diabetes Risk Test to find out if they are at risk for ... will light up the evening sky by programming the LAX pylons the color red. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):